# American Vanguard Corp: financial statements, quarterly

AVD · NYSE · CIK 5981 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avd.md) · [Financials](/companies/avd/financials.md) · [Filings](/companies/avd/filings.md) · [Insiders](/companies/avd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [150](/filings/0000950170-24-125626.md) | [172 d](/filings/0001193125-26-409138.md) | [135](/filings/0000950170-25-082654.md) | [128](/filings/0000950170-25-100730.md) | [118](/filings/0001193125-25-273381.md) | [166 d](/filings/0001193125-26-409138.md) | [116](/filings/0001193125-26-209203.md) | [129](/filings/0001193125-26-342489.md) | [119](/filings/0001193125-25-273381.md) | [151 d](/filings/0001193125-26-409138.md) | [124](/filings/0001193125-26-209203.md) | [117](/filings/0001193125-26-342489.md) |
| Cost of revenue | $m | [106](/filings/0000950170-24-125626.md) | [118 d](/filings/0001193125-26-409138.md) | [92.7](/filings/0000950170-25-082654.md) | [90.4](/filings/0000950170-25-100730.md) | [101](/filings/0001193125-25-273381.md) | [143 d](/filings/0001193125-26-409138.md) | [85.6](/filings/0001193125-26-209203.md) | [88.8](/filings/0001193125-26-342489.md) | [85.1](/filings/0001193125-25-273381.md) | [108 d](/filings/0001193125-26-409138.md) | [85.2](/filings/0001193125-26-209203.md) | [82.0](/filings/0001193125-26-342489.md) |
| Gross profit | $m | [43.1](/filings/0000950170-24-125626.md) | [54.6 d](/filings/0001193125-26-409138.md) | [42.4](/filings/0000950170-25-082654.md) | [37.8](/filings/0000950170-25-100730.md) | [17.3](/filings/0001193125-25-273381.md) | [22.8 d](/filings/0001193125-26-409138.md) | [30.2](/filings/0001193125-26-209203.md) | [40.5](/filings/0001193125-26-342489.md) | [34.2](/filings/0001193125-25-273381.md) | [42.6 d](/filings/0001193125-26-409138.md) | [38.4](/filings/0001193125-26-209203.md) | [34.7](/filings/0001193125-26-342489.md) |
| Research and development | $m | [9.1](/filings/0000950170-24-125626.md) | [10.7 d](/filings/0001193125-26-409138.md) | [5.7](/filings/0000950170-25-082654.md) | [8.6](/filings/0000950170-25-100730.md) | [11.2](/filings/0001193125-25-273381.md) | [7.2 d](/filings/0001193125-26-409138.md) | [5.7](/filings/0001193125-26-209203.md) | [5.8](/filings/0001193125-26-342489.md) | [5.7](/filings/0001193125-25-273381.md) | [6.0 d](/filings/0001193125-26-409138.md) | [5.3](/filings/0001193125-26-209203.md) | [6.5](/filings/0001193125-26-342489.md) |
| Selling, general and administrative | $m | [29.8](/filings/0000950170-24-125626.md) | [30.9 d](/filings/0001193125-26-409138.md) | [29.5](/filings/0000950170-25-082654.md) | [31.1](/filings/0000950170-25-100730.md) | [26.4](/filings/0001193125-25-273381.md) | [32.7 d](/filings/0001193125-26-409138.md) | [26.6](/filings/0001193125-26-209203.md) | [28.6](/filings/0001193125-26-342489.md) | [26.7](/filings/0001193125-25-273381.md) | [28.6 d](/filings/0001193125-26-409138.md) | [27.7](/filings/0001193125-26-209203.md) | [26.6](/filings/0001193125-26-342489.md) |
| Operating income | $m | [4.2](/filings/0000950170-24-125626.md) | [12.1 d](/filings/0001193125-26-409138.md) | [6.1](/filings/0000950170-25-082654.md) | [(9.2)](/filings/0000950170-25-100730.md) | [(28.4)](/filings/0001193125-25-273381.md) | [(70.0) d](/filings/0001193125-26-409138.md) | [(4.3)](/filings/0001193125-26-209203.md) | [4.4](/filings/0001193125-26-342489.md) | [(6.5)](/filings/0001193125-25-273381.md) | [(21.8) d](/filings/0001193125-26-409138.md) | [1.9](/filings/0001193125-26-209203.md) | [(0.3)](/filings/0001193125-26-342489.md) |
| Interest expense | $m | [3.4](/filings/0000950170-24-125626.md) | [4.4 d](/filings/0001193125-26-409138.md) | [3.7](/filings/0000950170-25-082654.md) | [3.9](/filings/0000950170-25-100730.md) | [4.4](/filings/0001193125-25-273381.md) | [4.6 d](/filings/0001193125-26-409138.md) | [3.8](/filings/0001193125-26-209203.md) | [4.5](/filings/0001193125-26-342489.md) | [4.9](/filings/0001193125-25-273381.md) | [5.3 d](/filings/0001193125-26-409138.md) | [5.8](/filings/0001193125-26-209203.md) | [9.1](/filings/0001193125-26-342489.md) |
| Income tax | $m | [0.9](/filings/0000950170-24-125626.md) | [0.7 d](/filings/0001193125-26-409138.md) | [1.5](/filings/0000950170-25-082654.md) | [(1.6)](/filings/0000950170-25-100730.md) | [(7.0)](/filings/0001193125-25-273381.md) | [13.0 d](/filings/0001193125-26-409138.md) | [0.4](/filings/0001193125-26-209203.md) | [0.8](/filings/0001193125-26-342489.md) | [0.4](/filings/0001193125-25-273381.md) | [1.1 d](/filings/0001193125-26-409138.md) | [0.1](/filings/0001193125-26-209203.md) | [0.4](/filings/0001193125-26-342489.md) |
| Net income | $m | [(0.3)](/filings/0000950170-24-125626.md) | [7.0 d](/filings/0001193125-26-409138.md) | [1.6](/filings/0000950170-25-082654.md) | [(11.7)](/filings/0000950170-25-100730.md) | [(25.7)](/filings/0001193125-25-273381.md) | [(90.4) d](/filings/0001193125-26-409138.md) | [(8.5)](/filings/0001193125-26-209203.md) | [(0.8)](/filings/0001193125-26-342489.md) | [(12.4)](/filings/0001193125-25-273381.md) | [(28.2) d](/filings/0001193125-26-409138.md) | [(4.1)](/filings/0001193125-26-209203.md) | [(9.9)](/filings/0001193125-26-342489.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0000950170-24-125626.md) | not reported | [0.06](/filings/0000950170-25-082654.md) | [(0.42)](/filings/0000950170-25-100730.md) | [(0.91)](/filings/0001193125-25-273381.md) | not reported | [(0.30)](/filings/0001193125-26-209203.md) | [(0.03)](/filings/0001193125-26-342489.md) | [(0.43)](/filings/0001193125-25-273381.md) | not reported | [(0.14)](/filings/0001193125-26-209203.md) | [(0.34)](/filings/0001193125-26-342489.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0000950170-24-125626.md) | not reported | [0.06](/filings/0000950170-25-082654.md) | [(0.42)](/filings/0000950170-25-100730.md) | [(0.91)](/filings/0001193125-25-273381.md) | not reported | [(0.30)](/filings/0001193125-26-209203.md) | [(0.03)](/filings/0001193125-26-342489.md) | [(0.43)](/filings/0001193125-25-273381.md) | not reported | [(0.14)](/filings/0001193125-26-209203.md) | [(0.34)](/filings/0001193125-26-342489.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.5](/filings/0000950170-23-061328.md) | [11.4](/filings/0001193125-26-409138.md) | [13.7](/filings/0000950170-24-057108.md) | [17.9](/filings/0000950170-24-094865.md) | [11.9](/filings/0000950170-24-125626.md) | [12.5](/filings/0001193125-26-409138.md) | [11.8](/filings/0001193125-26-209203.md) | [14.5](/filings/0001193125-26-342489.md) | [16.8](/filings/0001193125-25-273381.md) | [12.4](/filings/0001193125-26-409138.md) | [70.9](/filings/0001193125-26-209203.md) | [43.9](/filings/0001193125-26-342489.md) |
| Current assets | $m | [472](/filings/0000950170-23-061328.md) | [432](/filings/0000950170-25-078615.md) | [447](/filings/0000950170-24-057108.md) | [478](/filings/0000950170-24-094865.md) | [425](/filings/0000950170-24-125626.md) | [379](/filings/0001193125-26-409138.md) | [378](/filings/0000950170-25-082654.md) | [399](/filings/0000950170-25-100730.md) | [406](/filings/0001193125-25-273381.md) | [371](/filings/0001193125-26-409138.md) | [444](/filings/0001193125-26-209203.md) | [418](/filings/0001193125-26-342489.md) |
| Total assets | $m | [803](/filings/0000950170-23-061328.md) | [768](/filings/0000950170-25-078615.md) | [782](/filings/0000950170-24-057108.md) | [807](/filings/0000950170-24-094865.md) | [759](/filings/0000950170-24-125626.md) | [637](/filings/0001193125-26-409138.md) | [632](/filings/0000950170-25-082654.md) | [652](/filings/0000950170-25-100730.md) | [655](/filings/0001193125-25-273381.md) | [597](/filings/0001193125-26-409138.md) | [665](/filings/0001193125-26-209203.md) | [635](/filings/0001193125-26-342489.md) |
| Current liabilities | $m | [190](/filings/0000950170-23-061328.md) | [230](/filings/0000950170-25-078615.md) | [195](/filings/0000950170-24-057108.md) | [215](/filings/0000950170-24-094865.md) | [225](/filings/0000950170-24-125626.md) | [232](/filings/0001193125-26-409138.md) | [213](/filings/0000950170-25-082654.md) | [209](/filings/0000950170-25-100730.md) | [230](/filings/0001193125-25-273381.md) | [209](/filings/0001193125-26-409138.md) | [191](/filings/0001193125-26-209203.md) | [169](/filings/0001193125-26-342489.md) |
| Total liabilities | $m | [444](/filings/0000950170-23-061328.md) | [398](/filings/0000950170-25-078615.md) | [410](/filings/0000950170-24-057108.md) | [454](/filings/0000950170-24-094865.md) | [432](/filings/0000950170-24-125626.md) | [404](/filings/0001193125-26-409138.md) | [404](/filings/0000950170-25-082654.md) | [421](/filings/0000950170-25-100730.md) | [434](/filings/0001193125-25-273381.md) | [404](/filings/0001193125-26-409138.md) | [476](/filings/0001193125-26-209203.md) | [454](/filings/0001193125-26-342489.md) |
| Long-term debt | $m | [218](/filings/0000950170-23-061328.md) | [139](/filings/0000950170-25-078615.md) | [187](/filings/0000950170-24-057108.md) | [211](/filings/0000950170-24-094865.md) | [179](/filings/0000950170-24-125626.md) | [147](/filings/0001193125-26-409138.md) | [167](/filings/0000950170-25-082654.md) | [190](/filings/0000950170-25-100730.md) | [182](/filings/0001193125-25-273381.md) | [174](/filings/0001193125-26-409138.md) | [264](/filings/0001193125-26-209203.md) | [265](/filings/0001193125-26-342489.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-342489.md) | [2.3](/filings/0001193125-26-209203.md) | [2.3](/filings/0001193125-26-342489.md) |
| Short-term borrowings | $m | [0.0](/filings/0000950170-23-061328.md) | [0.0](/filings/0000950170-24-125626.md) | not reported | [0.0](/filings/0000950170-24-094865.md) | [0.0](/filings/0000950170-24-125626.md) | [0.0](/filings/0001193125-25-273381.md) | [0.0](/filings/0000950170-25-082654.md) | [0.0](/filings/0000950170-25-100730.md) | [0.0](/filings/0001193125-25-273381.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [359](/filings/0000950170-24-125626.md) | [370](/filings/0001193125-26-409138.md) | [372](/filings/0001193125-25-273381.md) | [353](/filings/0001193125-25-273381.md) | [328](/filings/0001193125-25-273381.md) | [233](/filings/0001193125-26-409138.md) | [227](/filings/0001193125-26-342489.md) | [231](/filings/0001193125-26-342489.md) | [221](/filings/0001193125-25-273381.md) | [192](/filings/0001193125-26-409138.md) | [190](/filings/0001193125-26-342489.md) | [181](/filings/0001193125-26-342489.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(49.3) d](/filings/0000950170-24-125626.md) | [87.1 d](/filings/0001193125-26-409138.md) | [(36.1)](/filings/0000950170-25-082654.md) | [(13.3) d](/filings/0000950170-25-100730.md) | [27.9 d](/filings/0001193125-25-273381.md) | [25.4 d](/filings/0001193125-26-409138.md) | [(20.6)](/filings/0001193125-26-209203.md) | [(19.3) d](/filings/0001193125-26-342489.md) | [12.7 d](/filings/0001193125-25-273381.md) | [6.0 d](/filings/0001193125-26-409138.md) | [(35.4)](/filings/0001193125-26-209203.md) | [(25.0) d](/filings/0001193125-26-342489.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [0.8 d](/filings/0000950170-24-125626.md) | [0.8 d](/filings/0001193125-26-409138.md) | [0.8](/filings/0000950170-25-082654.md) | [0.8 d](/filings/0000950170-25-100730.md) | [0.8 d](/filings/0001193125-25-273381.md) | [0.0 d](/filings/0001193125-26-409138.md) | [0.0](/filings/0000950170-25-082654.md) | [0.0 d](/filings/0000950170-25-100730.md) | [0.0 d](/filings/0001193125-25-273381.md) | [0.0 d](/filings/0001193125-26-409138.md) | not reported | not reported |
| Share repurchases | $m | [8.3 d](/filings/0000950170-24-125626.md) | [0.0 d](/filings/0001193125-26-409138.md) | [0.0](/filings/0000950170-24-057108.md) | [0.0 d](/filings/0000950170-24-094865.md) | [0.0 d](/filings/0000950170-24-125626.md) | [0.0 d](/filings/0001193125-26-409138.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.8](/filings/0000950170-23-061328.md) | [29.1](/filings/0000950170-24-057108.md) | [28.4](/filings/0000950170-24-094865.md) | [27.9](/filings/0000950170-24-125626.md) | [28.1](/filings/0000950170-25-082654.md) | [28.0](/filings/0000950170-25-100730.md) | [28.2](/filings/0001193125-25-273381.md) | [28.3](/filings/0001193125-26-209203.md) | [28.3](/filings/0001193125-26-342489.md) | [28.5](/filings/0001193125-25-273381.md) | [28.6](/filings/0001193125-26-209203.md) | [28.6](/filings/0001193125-26-342489.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,500,632 at 2026-08-04, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342489.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.